摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-phenyl-2-[5-[(1S)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]tetrazol-1-yl]propanoic acid

中文名称
——
中文别名
——
英文名称
3-phenyl-2-[5-[(1S)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]tetrazol-1-yl]propanoic acid
英文别名
——
3-phenyl-2-[5-[(1S)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]tetrazol-1-yl]propanoic acid化学式
CAS
——
化学式
C26H25N5O4
mdl
——
分子量
471.5
InChiKey
YTADYLYVKYDYGF-NQCNTLBGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    35
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    119
  • 氢给体数:
    2
  • 氢受体数:
    7

文献信息

  • Immunomodulators
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20160222060A1
    公开(公告)日:2016-08-04
    The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    本公开提供了一种新型的大环肽,可以抑制PD-1/PD-L1和PD-L1/CD80蛋白质相互作用,因此对于改善包括癌症和传染性疾病在内的各种疾病是有用的。
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    申请人:Bristol-Myers Squibb Company
    公开号:US20140294898A1
    公开(公告)日:2014-10-02
    The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    本公开提供了新型大环肽,其能够抑制PD-1/PD-L1和PD-L1/CD80蛋白质/蛋白质相互作用,因此可用于改善各种疾病,包括癌症和传染性疾病。
  • Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20160340391A1
    公开(公告)日:2016-11-24
    The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
  • IMMUNOMODULATORS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20170283462A1
    公开(公告)日:2017-10-05
    The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
  • US9308236B2
    申请人:——
    公开号:US9308236B2
    公开(公告)日:2016-04-12
查看更多